Table of Contents Author Guidelines Submit a Manuscript
Malaria Research and Treatment
Volume 2011, Article ID 703730, 5 pages
http://dx.doi.org/10.4061/2011/703730
Review Article

Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals

1Infectious Diseases Institute and Infectious Diseases Network for Treatment and Research in Africa (INTERACT), Makerere University College of Health Sciences, P.O. Box 7061, Kampala, Uganda
2Department of Pharmacology and Therapeutics, Trinity College Dublin 2, Ireland
3Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3BX, UK
4International Health, Epidemiology en Social Medicine, Universiteit Antwerpen, Universiteitsplein 1, 2610 Antwerp, Belgium

Received 14 December 2010; Accepted 14 February 2011

Academic Editor: Neena Valecha

Copyright © 2011 Pauline Byakika-Kibwika et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Malaria and HIV and Their Implications for Public Policy, World Health Organisation, Geneva, Switzerland, 2005.
  2. V. Chalwe, J. P. Van Geertruyden, D. Mukwamataba et al., “Increased risk for severe malaria in HIV-1-infected adults, Zambia,” Emerging Infectious Diseases, vol. 15, no. 5, pp. 749–755, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. C. Piscitelli and K. D. Gallicano, “Interactions among drugs for HIV and opportunistic infections,” The New England Journal of Medicine, vol. 344, no. 13, pp. 984–996, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Abdulla, I. Sagara, S. Borrmann et al., “Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial,” The Lancet, vol. 372, no. 9652, pp. 1819–1827, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Abdulla and I. Sagara, “Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children,” Malaria Journal, vol. 8, supplement 1, article S7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Omari, C. Gamble, and P. Garner, “Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria,” Cochrane Database of Systematic Reviews, no. 2, p. CD005965, 2006. View at Google Scholar · View at Scopus
  7. A. A. Omari, C. Gamble, and P. Garner, “Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria,” Cochrane Database of Systematic Reviews, no. 4, p. CD005564, 2005. View at Google Scholar · View at Scopus
  8. N. J. White, M. Van Vugt, and F. Ezzet, “Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine,” Clinical Pharmacokinetics, vol. 37, no. 2, pp. 105–125, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Ezzet, M. Van Vugt, F. Nosten, S. Looareesuwan, and N. J. White, “Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 3, pp. 697–704, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. N. J. White, M. Van Vugt, and F. Ezzet, “Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine,” Clinical Pharmacokinetics, vol. 37, no. 2, pp. 105–125, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. G. Premji, S. Abdulla, B. Ogutu et al., “The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence,” Malaria Journal, vol. 7, article 244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Ezzet, R. Mull, and J. Karbwang, “Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients,” British Journal of Clinical Pharmacology, vol. 46, no. 6, pp. 553–561, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Makanga and S. Krudsood, “The clinical efficacy of artemether/lumefantrine (Coartem®),” Malaria Journal, vol. 8, no. 1, article S5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. van Vugt, P. Wilairatana, B. Gemperli et al., “Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria,” American Journal of Tropical Medicine and Hygiene, vol. 60, no. 6, pp. 936–942, 1999. View at Google Scholar · View at Scopus
  15. M. Van Vugt, S. Looareesuwan, P. Wilairatana et al., “Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 94, no. 5, pp. 545–548, 2000. View at Google Scholar · View at Scopus
  16. G. Lefèvre, S. Looareesuwan, S. Treeprasertsuk et al., “A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand,” American Journal of Tropical Medicine and Hygiene, vol. 64, no. 5-6, pp. 247–256, 2001. View at Google Scholar · View at Scopus
  17. C. Hatz, J. Soto, H. D. Nothdurft et al., “Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in non-immune populations: a safety, efficacy, and pharmacokinetic study,” American Journal of Tropical Medicine and Hygiene, vol. 78, no. 2, pp. 241–247, 2008. View at Google Scholar · View at Scopus
  18. A. Yeka, G. Dorsey, M. R. Kamya et al., “Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda,” PLoS ONE, vol. 3, no. 6, article e2390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. R. Kamya, A. Yeka, H. Bukirwa et al., “Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial,” PLoS Clinical Trials, vol. 2, no. 5, article e20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Kabanywanyi, A. Mwita, D. Sumari, R. Mandike, K. Mugittu, and S. Abdulla, “Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania,” Malaria Journal, vol. 6, Article ID 146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Bukirwa, Y. Adoke, M. R. Kamya et al., “Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda,” Plos Clinical Trials, vol. 1, no. 1, article e7, 2006. View at Google Scholar
  22. J. P. Van Geertruyden, M. Mulenga, L. Mwananyanda et al., “HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria,” Journal of Infectious Diseases, vol. 194, no. 7, pp. 917–925, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Falade, M. Makanga, Z. Premji, C. E. Ortmann, M. Stockmeyer, and P. Ibarra de Palacios, “Efficacy and safety of artemether-lumefantrine (Coartem®) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 99, no. 6, pp. 459–467, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. Advisory Committee Briefing Book, “Coartem® (artemether/lumefantrine) tablets for the treatment of malaria in patients with acute, uncomplicated infections due to Plasmodium falciparum or mixed infections including P.falciparum,” http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-02-Novartis.pdf, 2008.
  25. C. Falade and C. Manyando, “Safety profile of Coartem®: the evidence base,” Malaria Journal, vol. 8, supplement 1, article S6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Golenser, J. H. Waknine, M. Krugliak, N. H. Hunt, and G. E. Grau, “Current perspectives on the mechanism of action of artemisinins,” International Journal for Parasitology, vol. 36, no. 14, pp. 1427–1441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. F. T. Aweeka and P. I. German, “Clinical pharmacology of artemisinin-based combination therapies,” Clinical Pharmacokinetics, vol. 47, no. 2, pp. 91–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Khoo, D. Back, and P. Winstanley, “The potential for interactions between antimalarial and antiretroviral drugs,” AIDS, vol. 19, no. 10, pp. 995–1005, 2005. View at Google Scholar · View at Scopus
  29. N. J. White, “Preventing antimalarial drug resistance through combinations,” Drug Resistance Updates, vol. 1, no. 1, pp. 3–9, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Djimdé and G. Lefèvre, “Understanding the pharmacokinetics of Coartem®,” Malaria Journal, vol. 8, supplement 1, article S4, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Kokwaro, L. Mwai, and A. Nzila, “Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria,” Expert Opinion on Pharmacotherapy, vol. 8, no. 1, pp. 75–94, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Travassos and M. K. Laufer, “Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations,” Pediatric Research, vol. 65, no. 5, pp. 64R–70R, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Hoffmann, J. K. Rockstroh, and B. S. Kamps, HIV Medicine, Flying, Paris, Farnce, 2005.
  34. A. Tseng and R. D. MacArthur, “Profile of etravirine for the treatment of HIV infection,” Therapeutics and Clinical Risk Management, vol. 6, no. 1, pp. 49–58, 2010. View at Google Scholar · View at Scopus
  35. D. Podzamczer and E. Fumero, “The role of nevirapine in the treatment of HIV-1 disease,” Expert Opinion on Pharmacotherapy, vol. 2, no. 12, pp. 2065–2078, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Back, S. Gibbons, and S. Khoo, “Pharmacokinetic drug interactions with nevirapine,” Journal of Acquired Immune Deficiency Syndromes, vol. 34, supplement 1, pp. S8–S14, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Colafigli, S. Di Giambenedetto, L. Bracciale et al., “Long-term follow-up of nevirapine-treated patients in a single-centre cohort,” HIV Medicine, vol. 10, no. 8, pp. 461–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Rivero, J. A. Mira, and J. A. Pineda, “Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 3, pp. 342–346, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Y. Rakhmanina and J. N. van den Anker, “Efavirenz in the therapy of HIV infection,” Expert Opinion on Drug Metabolism and Toxicology, vol. 6, no. 1, pp. 95–103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. S. M. E. Vrouenraets, F. W. N. M. Wit, J. van Tongeren, and J. M. A. Lange, “Efavirenz: a review,” Expert Opinion on Pharmacotherapy, vol. 8, no. 6, pp. 851–871, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. G. O. Adjei, K. Kristensen, B. Q. Goka et al., “Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 12, pp. 4400–4406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Hoffmann, J. K. Rockstroh, and B. S. Kamps, HIV Medicine, Flying, Paris, France, 2006.
  43. A. H. Corbett, M. L. Lim, and A. D. M. Kashuba, “Kaletra (lopinavir/ritonavir),” Annals of Pharmacotherapy, vol. 36, no. 7-8, pp. 1193–1203, 2002. View at Google Scholar · View at Scopus
  44. G. N. Kumar, V. K. Jayanti, M. K. Johnson et al., “Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans,” Pharmaceutical Research, vol. 21, no. 9, pp. 1622–1630, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. P. German, S. Parikh, J. Lawrence et al., “Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 4, pp. 424–429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Tamara, K. Mauff, P. Smith et al., “Nevirapine increases lumefantrine exposure in HIV-infected patients,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif, USA, 2010.
  47. J. G. Kublin, P. Patnaik, C. S. Jere et al., “Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study,” The Lancet, vol. 365, no. 9455, pp. 233–240, 2005. View at Publisher · View at Google Scholar · View at Scopus